TGTX Stock TG Therapeutics, Inc.
Today’s call · TGTX
All live ideas →5 of 6 technical checks lean bullish
TGTX is in an uptrend, momentum firm. $66.12 is the level overhead; $60 the first support below.
- A close above $66.12 on rising volume (breakout).
- A pullback to $60 that holds (entry near support).
The brief
All readings
Levels that matter
Compare with…
TG Therapeutics (TGTX) stock analysis, November 20, 2026: bullish outlook with high conviction
TG Therapeutics (TGTX) closed at $63.39 on November 20, 2026, after slipping 2.3% on the day but still sitting well above its 40‑week average and the 52‑week high of $66.12 remains within reach. The balance of evidence leans strongly positive for the next two to six weeks, driven by a daily trend that mirrors a weekly uptrend, outperformance versus the S&P 500 and the healthcare sector, and a breakout math that still favours upside despite a modest reward‑to‑risk profile. The stock’s long‑term thesis remains intact, with the price holding above key structural support and the next earnings report poised to test the upside narrative.
Why it matters
The recent price action reflects a market that has already priced in a modest correction after a sharp rally of 19% over the past month and a 59% gain over six months. The 5‑day move shows the stock down 1.74% while the S&P 500 fell 8.07% and the XLV health‑care ETF dropped 5.85%, leaving TGTX outperforming the broader market by roughly 4.1 percentage points. This outperformance indicates that investors still view the company’s fundamentals as stronger than the sector’s recent weakness.
With the daily trend aligned to a weekly uptrend and the price sitting above both its 50‑day ($57.58) and 200‑day ($46.25) simple moving averages, the longer‑term bias remains upward. The stock’s relative strength index at 57.3 suggests neither extreme overbought nor oversold conditions, supporting a continuation of the current trend rather than a near‑term reversal.
Analyst sentiment is overwhelmingly positive: seven analysts rate TGTX a strong buy, with a mean price target of $69.43, only 8.7% above the current price. The consensus target range of $21 to $86 underscores a wide upside potential, though the lower bound reflects a floor that many analysts consider unlikely given the structural support at $60.
There is no recent news to explain the day’s dip; the market reaction appears to be a broader equity sell‑off rather than company‑specific information. The lack of a catalyst means the price movement is more a function of market sentiment and sector dynamics than new fundamentals.
What the evidence says
On the long‑term view, the thesis that TGTX is in an uptrend remains intact. The price is above its 40‑week average, the 52‑week high of $66.12 is only 4.1% away, and the stock has outperformed the S&P 500 by 20.7% over the past 50 days. These factors keep the long‑term outlook bullish.
For the next two to six weeks, the balance of evidence leans positive with high conviction. The assessment cites three of four conviction points: the daily trend runs with the weekly uptrend, the stock leads the S&P 500 by 20.7% over 50 days, and it leads the XLV sector by 9.3% over the same period. The breakout math points to upside potential, though the reward‑to‑risk ratio does not meet a 3‑to‑1 threshold. The strongest case against this reading would be a failure to break above the 52‑week high of $66.12 on volume that exceeds the 20‑day average, which would keep the reward‑to‑risk below 1.0 and could trigger a re‑evaluation of the short‑term bias.
Levels that matter
The structure holds the price above $60, a round level that also serves as the first crack point. Below $60, the next structural support is the 50‑day SMA at $57.58; a close beneath that would signal the end of the current uptrend. The trend‑ending level is therefore $57.58, aligning with the rule that a weekly close below this SMA would change the picture.
The breakout level is a daily close above $66.12, the 52‑week high, on volume above the 20‑day average. If achieved, the math yields two targets: $70 (reward‑to‑risk 0.6) and $80 (reward‑to‑risk 2.0). Because the reward‑to‑risk does not reach 3‑to‑1, a price of roughly $84 would be required for the math to meet that threshold, which is beyond the current target range.
What would change the picture
A weekly close below the 50‑day SMA at $57.58 would invalidate the current uptrend and shift the narrative toward a downtrend. Additionally, any unexpected negative earnings surprise on November 9, such as a miss on revenue or guidance, could also alter the outlook regardless of price action.
What to watch
- November 9 earnings – focus on the earnings per share figure and guidance for the next quarter.
- Sector moves – watch XLV performance and any health‑care policy news that could affect biotech sentiment.
- Valuation – the consensus mean target of $69.43 implies a modest upside of about 9% from the current price, keeping the stock attractive relative to its analyst spread.